

# A Concise Guide to Jump Start Your Ramsay Research Proposal

---

## 2021 Cycle

Welcome to this introductory guide. We hope the information inside is useful as you develop your research proposal. The purpose of this toolkit is to:

- Provide a brief (by no means comprehensive) overview of the state of play in ME/CFS research
- Share what we know so far in the **new field of long-COVID** research
- Put forward intriguing disease models to be interrogated
- Outline key considerations and resources, including details of the You + ME Registry and Biobank
- List promising approaches to ME/CFS and long-COVID research that could accelerate progress to understand and treat these conditions



# TABLE OF CONTENTS

<i>Title</i>	<i>Page</i>
<a href="#"><u>Overview of ME/CFS &amp; Long-COVID</u></a> .....	3
<a href="#"><u>ME/CFS Disease Models</u></a> .....	4
<a href="#"><u>ME/CFS Research Landscape</u></a> .....	5
<a href="#"><u>ME/CFS Research Considerations</u></a> .....	7
<a href="#"><u>Long COVID Research Landscape</u></a> .....	8
<a href="#"><u>Resources for Patient Data &amp; Samples</u></a> .....	9
<a href="#"><u>Approaches to Research</u></a> .....	10

# ME/CFS

Myalgic encephalomyelitis (also known as chronic fatigue syndrome or **ME/CFS**) is a disease characterized by central nervous system and immune system disturbances, neurological and autonomic symptoms, circulatory abnormalities, and altered metabolism. Nearly [75% report that an infection](#) preceded the development of their ME/CFS illness. The cardinal symptom is malaise and exacerbation of symptoms following minimal physical or mental exertion that is not relieved by rest or sleep, which can last days or even weeks. A remitting and relapsing disease course is common. Read more about the features of ME/CFS in the [2015 National Academy of Medicine Report](#).

## Long-COVID

Although most recover from COVID-19, a subset of people (estimates suggest 10% or more) suffer from health impacts long after the expected recovery period, even months after the initial infection. Research into the phenomenon known as “**long-COVID**” is in nascent stages and much is unknown, but [patient-led surveys](#) demonstrate that long-COVID involves a multitude of respiratory, neurological, cardiovascular and gastrointestinal manifestations. A common feature of the illness are relapsing and remitting symptoms; patients improve, only to be struck back down again.

## What’s the connection between ME/CFS and Long-COVID?

**Dr. Anthony Fauci**, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, has acknowledged [a number of long-COVID cases are “strikingly similar” to ME/CFS](#). This connection is not without precedent – a number of other pathogens have been connected to ME/CFS and post-viral illness. In a previous outbreak of a similar type of coronavirus infection called Severe Acute Respiratory Syndrome (SARS), persistent health impairments were experienced by a number of survivors.

It is imperative that we study the recovery period and the long-term impacts of COVID-19, including in those with mild or moderate illness in the acute stage. What we learn about the prevention and treatment of long-COVID may help further our understanding of ME/CFS and our ability to help those patients as well.

[Read more >>> an opinion article from Dr. Anthony L. Komaroff and Dr. Cindy Bateman on behalf of the U.S. ME/CFS Clinician Coalition.](#)

# 5 PROPOSED ME/CFS DISEASE MODELS

*As outlined by Anthony L. Komaroff, MD at the  
April 2019 NIH conference on ME/CFS*

*For Dr. Komaroff's full slides click [here](#)*

*Watch a recording of his talk at 06:02:00 [here](#)*

1

**Excessive cellular  
senescence with  
generation of  
fatigue-inducing  
molecules**

2

**Cell danger  
response/incomplete  
healing**

3

**Sickness  
behavior/inflammation**

4

**Microbiome as the source of  
immune system activation  
and inflammation**

5

**Dauer/hibernation-torpor, in  
which energy-producing  
reactions are reduced to a  
minimum in response to  
some insult**

**ALSO. . .** Check out some  
disease models proposed by  
Ramsay Investigators:

- Stimulation of microglia by mast cells in the hypothalamus  
[Hatziagelaki et al.](#)
- Infection-elicited autoimmunity  
[Blomberg et al.](#)
- Pathogen-induced dysfunction  
[Proal & Marshall](#)

# ME/CFS RESEARCH LANDSCAPE

Understanding of the pathogenesis of ME/CFS has increased considerably in recent decades and a complex picture of the disease has emerged, implicating many systems and a variety of mechanisms >>>



## GENETICS

- Clustering patterns are seen in families and there is need of genome-wide association studies to identify candidate SNPs
- There is growing evidence that epigenetic patterns are different between patients and matched healthy controls and research has shown [differentially methylated pathways](#) related to immune response, glucocorticoid receptors, and metabolism.
- In-depth investigation of epigenetic mechanisms other than DNA methylation are lacking in ME/CFS, [but increased HDAC expression](#), an [upregulation of microRNA](#) related to cell cycle and immune regulation, and methylation changes [associated with BDNF levels](#) have been described.
- ME/CFS patients have also been found to [meet the criteria for Ehlers-Danlos Syndrome](#) (which often runs in families)

- Research groups have found differences in ME/CFS blood cytokine signatures; some identifying patterns correlated with [disease severity](#) and others [duration](#) of illness. A recent paper pointed out the noisiness in peripheral cytokine data and urged [caution in over-interpreting findings](#)
- There is evidence of defective cell-mediated immunity, especially in [NK cells](#), and increasing interest in T cell activation
- Mechanisms of [autoimmunity](#) have been explored; selective removal of autoantibodies has proved effective in small cohorts
- [Altered B cell phenotypes](#) have been uncovered
- Findings of deviations in the immune system [are notably inconsistent](#), possibly due to patient heterogeneity and selection, the cyclical nature of the disease, and methodology





## IMMUNOLOGY

- Many patients report experiencing an infection preceding the development of ME/CFS and various pathogenic triggers have been considered, including HHV-6/7, EBV, enteroviruses, others
- Lacking [clear evidence of chronic infection](#), researchers have focused on a [“hit and run” hypothesis](#) or viral reactivation
- [Alterations in the gut microbiome](#) composition of people with ME/CFS have been uncovered by different groups; it’s hypothesized a “leaky gut” may trigger immune dysfunction and/or gut inflammation might disrupt bidirectional communication with the brain



## MICROBIOME

- There is considerable evidence demonstrating that ME/CFS has both structural and functional brain consequences, such as [reduced functional connectivity](#) and [changes in cerebral blood flow](#), (CBF) including [reductions in CBF](#) during upright tilt table testing.
- Indicators of brain inflammation have been found in [MRS](#) and [PET](#) neuroimaging studies. The [brainstem has been argued to be a target](#) for future studies as it has explanatory power for autonomic dysfunction seen in patients and is a gap from previous research
- Inflammatory markers have been found in [cerebrospinal fluid of patients](#)
- Neuroendocrine changes, particularly [HPA axis dysfunction](#), have been explored
- Findings from a small pilot study suggest that [small-fiber polyneuropathy](#) might underlie ME/CFS symptoms
- Mechanical causes of ME/CFS, such as [craniocervical instability](#) and [cervical spinal stenosis](#) have been described in patient recovery stories and case series



- Cardiovascular symptoms and circulatory abnormalities, including [impaired cardiac function](#) and altered blood pressure regulation, have been described in ME/CFS
- The majority of studies in young people show a [high prevalence of OI](#)
- [Reduced heart rate variability](#) has been correlated with fatigue severity in patients
- [Preload failure](#) and indications of insufficient uptake of oxygen in the skeletal muscle cells have been observed in patients, which could be the result of circulatory problems or mitochondrial dysfunction
- A small study found evidence [of endothelial dysfunction](#) in large and small vessels

- [Mitochondrial dysfunction](#), [AMPK impairment](#), and [redox imbalance](#) have all been associated with ME/CFS.
- The body of evidence points to irregularities in various metabolic pathways, including changes in [lipid](#) and amino acid pathways, nucleotide, nitrogen, and hormone metabolism. Overall, different groups have found evidence to support a [hypometabolic state](#)
- There has been some exploration whether [metabolic dysfunction in immune cells](#) could be driving problems with immune system functioning in ME/CFS patients.
- A recent study found [bioenergetic defects in muscle cells](#), suggesting that energy production problems could be body-wide



# ME/CFS RESEARCH CONSIDERATIONS

## ME/CFS PATIENT SELECTION

The ME/CFS field [lacks an agreed upon research or clinical case definition](#).

*Click the image to view an overview of case definitions from Open Medicine Foundation*

Sample heterogeneity across research studies and disordered patient selection impedes replication and holds back progress in the search for biological markers and effective treatments.

HOPE		HOLMES 1989	FUKUDA 1994	CANADIAN CONSENSUS CRITERIA 2003	INTERNATIONAL CONSENSUS CRITERIA 2011	INSTITUTE OF MEDICINE 2016
DETAILED CRITERIA FOR ME/CFS DIAGNOSIS						
NAMING	CFS	CFS	ME/CFS	ME	SEID	
NEW ONSET	REQUIRED	REQUIRED	REQUIRED	REQUIRED	REQUIRED	
FUNCTIONAL IMPAIRMENT	50% DECREASED	SUBSTANTIAL	SUBSTANTIAL	50% DECREASED	SUBSTANTIAL	
MINIMAL DURATION	6 MONTHS	6 MONTHS	6 MONTHS	NO MINIMUM	6 MONTHS	
SYMPTOM REQUIREMENTS FOR EACH DIAGNOSTIC CRITERIA						
SYMPTOM CATEGORIES	PERSISTENT FATIGUE	REQUIRED	REQUIRED	REQUIRED		REQUIRED
	COGNITION PROBLEMS (CP)			2 SYMPTOMS REQUIRED FROM ANY OF THESE 3 CATEGORIES		EITHER CP OR DI
	MOTOR-SENSORY DISTURBANCES			REQUIRED		
	SHORT TERM MEMORY ISSUES			REQUIRED		
	PAIN	8 SYMPTOMS REQUIRED FROM ANY OF THESE 6 CATEGORIES	4 SYMPTOMS REQUIRED FROM ANY OF THESE 4 CATEGORIES	REQUIRED	1 SYMPTOM REQUIRED FROM 1 OF THESE 5 CATEGORIES	
	SLEEP DISTURBANCES			REQUIRED		REQUIRED
	POST-EXERTIONAL MALAISE			REQUIRED	REQUIRED	REQUIRED
	RECURRENT FLU-LIKE SYMPTOMS			1 SYMPTOM REQUIRED FROM ANY OF THESE 4 CATEGORIES		
	INFECTION SUSCEPTIBILITY				1 SYMPTOM REQUIRED FROM 2 OF THESE 2 CATEGORIES	
	SENSITIVITIES FOOD/CHEMICALS					
	GASTRO-INTESTINAL TRACT ISSUES			1 SYMPTOM REQUIRED FROM ANY OF THESE 3 CATEGORIES		
	CENTROBRYNARY PROBLEMS					
	ORTHOSTATIC INTOLERANCE (OI)					EITHER CP OR DI
RESPIRATORY PROBLEMS				1 SYMPTOM REQUIRED FROM ANY OF THESE 4 CATEGORIES		
CARDIOVASCULAR PROBLEMS						
INTOLERANCE OF TEMPERATURE				1 SYMPTOM REQUIRED FROM ANY OF THESE 6 CATEGORIES		
THERMOSTATIC INSTABILITY						

We don't have the space to outline the arguments for one case definition over another in this guide, but this is unequivocal:



A well-designed study will **require the presence of post-exertional malaise (PEM)** in determining a case of ME/CFS.

## DATA COLLECTION INSTRUMENTS

### NINDS COMMON DATA ELEMENTS FOR ME/CFS

*Start up resources from the NINDS CDEs can be accessed [here](#)*



Please note a few things:

- a method for ascertaining and recording the presence or absence of PEM as a case defining symptom is imperative
- The DePaul Symptom Questionnaire should be considered as a core instrument over the Symptom Checklist
- The use of a method to assess functional status, like the [Karnofsky score](#), should be used along with a quality of life assessment

# LONG-COVID RESEARCH LANDSCAPE

Research into the phenomenon known as “long-COVID” is in nascent stages and much is unknown. It is imperative its features, trajectory, and biology are tracked and studied. Here are some key research efforts and observations so far >>>

- Multiple organs, in addition to [lungs](#), are implicated in long-term damage and impacts of COVID:
  - There is [evidence SARS-CoV-2 can infect the brain](#), causing neuroinflammation and neurological symptoms.
  - Clinical studies have pointed to [cardiovascular consequences](#).
  - Damage across multiple organ systems has been observed even in [non-hospitalized individuals](#)
- Some patients are experiencing lingering symptoms even without evidence of organ damage. [Patient-led surveys](#) have documented:
  - A multitude of respiratory, neurological, cardiovascular and gastrointestinal symptoms that persist many months past the initial infection; even in those with mild or moderate illness in the acute phase.
  - Relapsing and remitting symptoms.
  - Experience of exertional intolerance and post-exertional malaise (PEM), a hallmark symptom of ME/CFS in which minimal activity triggers a relapse of exhaustion, cognitive problems, and other symptoms.
- Preliminary reports and data about long-COVID symptoms and patient experiences contain many similarities to other chronic illnesses known to be associated with viral triggers, such as: ME/CFS, [postural orthostatic tachycardia syndrome \(POTS\)](#), other forms of dysautonomia, and Mast Cell Activation Syndrome (MCAS), just to name a few.



# RESOURCES FOR PATIENT DATA & SAMPLES

Resources available through Solve M.E. and other biorepositories. Click the logos to learn more>>>



## Study Subjects

2,003 ME/CFS  
305 Healthy Controls  
322 long-COVID

## Available Data

The You + ME Registry questionnaires include Demographics, SF-36, Karnofsky Performance Scale, Multidimensional Fatigue Inventory, Symptoms Assessment (maps to ME/CFS case criteria), ME/CFS Disease History (ME/CFS only), COVID-19 History, Medications, Comorbidities, Beighton. A subset of participants track symptoms and other factors over time through a mobile app. All data are de-identified to protect participant privacy.

## Biospecimens (collection planned on subset of total cohort in early 2021)

Dried Blood Spot Cards  
Other sample types on request

Please email [research@solvecfs.org](mailto:research@solvecfs.org) for more information



## Study Subjects

235 ME/CFS  
110 Healthy Controls

## Available Data

The questionnaires administered to the SolveCFS Biobank participants include Medical History, Demographics, Symptoms, Medications, SF-36, Fibromyalgia Impact Questionnaire-R. All data are de-identified to protect participant privacy.

## Available Biospecimens

PBMC, Plasma

Please email [research@solvecfs.org](mailto:research@solvecfs.org) for more information

CUREME

Leading research into ME/CFS

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



# APPROACHES TO RESEARCH THAT COULD MOVE THE NEEDLE

- Studies designed to **interrogate post-exertional malaise (PEM)**, a key feature of ME/CFS and a symptom that has already been observed in some long COVID patients
- Studies aimed at identifying **subgroups**
- Provocation (**exercise protocol**) studies. There is evidence that an exercise protocol has more value than measurements taken at rest to determine biological differences in people with ME/CFS. This might also be true for people with long COVID
- **Longitudinal characterization**. Moving away from cross-sectional studies to the collection of information at multiple time points
- Include **disease controls** (e.g. multiple sclerosis, Gulf War Illness, fibromyalgia) along with healthy controls, and design studies to compare ME/CFS, long-COVID and those who fully recovered from COVID
- **Cross-disciplinary research** that can dig into the multiple systems indicated in the disease
- **Stratification analyses** by age, sex, severity, duration, type of onset/triggering event, symptoms, comorbid conditions, functional status
- Utilizing high-powered methodologies, including **multi-omics** and **machine-learning** approaches, and novel techniques, like **examining exosomes**

Would you like help with:

- Connecting with a ME/CFS or long-COVID expert?
- Identifying a collaborator?
- Accessing patient and control samples from Solve ME's Registry & Biobank?

*Email us with these and other questions at  
[research@solvecfs.org](mailto:research@solvecfs.org)*

